-
Berbamine Hydrochloride: NF-κB to Ferroptosis
2026-09-15
Berbamine hydrochloride offers a strategically useful research probe for connecting NF-κB, STAT3, calcium homeostasis, and ferroptosis biology. This article translates recent findings on the METTL16–SENP3–LTF axis into a disciplined experimental framework for leukemia and hepatocellular carcinoma models while distinguishing established evidence from testable hypotheses.
-
Deracoxib: From COX-2 Biology to Translational Design
2026-09-15
A translational perspective on Deracoxib that connects selective COX-2 biology with canine inflammation, osteosarcoma models, assay design, exposure constraints, and evidence-led cancer research strategy.
-
Dexamethasone: Applied Workflow Guide
2026-09-14
Dexamethasone (DHAP) is a versatile glucocorticoid anti-inflammatory reagent for modeling NF-κB regulation, stem-cell differentiation, osteosarcoma growth, and neuroinflammation. This practical guide connects assay design, formulation, timing, controls, and troubleshooting to help researchers obtain interpretable, reproducible results.
-
NEDD4L–PRMT5 Axis in Colorectal Cancer Metastasis
2026-09-14
The 2025 Advanced Science study identifies the HECT E3 ligase NEDD4L as a suppressor of colorectal cancer liver metastasis through targeted degradation of PRMT5. Its in vivo screening and mechanistic validation connect NEDD4L-dependent PRMT5 turnover with reduced AKT1 arginine methylation, AKT/mTOR signaling, tumor-cell proliferation, and metastatic colonization.
-
Dihydrotestosterone: Practical Signaling Workflows
2026-09-13
Dihydrotestosterone (DHT) enables controlled interrogation of androgen receptor signaling in bladder cancer and muscle-focused disease models. This guide translates product specifications and pathway evidence into executable dosing, control, troubleshooting, and assay-design strategies.
-
Losartan in Podocyte and Vascular Research
2026-09-12
Losartan is an angiotensin II receptor antagonist that can anchor mechanistic studies spanning vascular remodeling and diabetic kidney disease. This article explains how to use it as an AT1-pathway comparator alongside the FGF4-FGFR1 podocyte-survival axis, with practical assay-design guidance.
-
JNJ-10198409: PDGF Receptor Inhibition Workflows
2026-09-12
JNJ-10198409 provides a nanomolar, ATP-competitive way to dissect PDGF-BB-driven signaling, proliferation, migration, and angiogenic behavior. This workflow-centered guide connects acute phospho-signaling assays with longer tumor, vascular, and fibrotic disorder research models while emphasizing controls, timing, and troubleshooting.
-
C34 TLR4 Inhibitor: Workflows for Inflammation
2026-09-11
C34 is a selective small molecule TLR4 inhibitor for separating LPS-driven inflammation from TLR2 or TLR9 signaling in macrophage and intestinal models. This practical guide covers reagent handling, dose-response design, necrotizing enterocolitis research, and comparison with plant-derived interventions in neuroinflammation studies.
-
Trichostatin A (TSA) Workflow for HDAC Studies
2026-09-11
Trichostatin A (TSA) provides a reversible way to connect histone hyperacetylation with proliferation, differentiation, and cell-cycle phenotypes. This workflow combines practical dosing guidance with orthogonal readouts and a careful interpretation of TSA alongside the SIRT1–Plk2 centrosome mechanism.
-
NET-DNA, CCDC25, and ILC3 Repair in UC
2026-09-10
A 2026 FASEB Journal study identifies NET-derived DNA as an inhibitor of intestinal epithelial repair, linking NET-DNA exposure to CCDC25-dependent suppression of IL-22 production by group 3 innate lymphoid cells. Its combined mouse, cellular, transcriptomic, and barrier assays provide a mechanistic framework for studying how innate immune signals impair mucosal healing in ulcerative colitis.
-
SB525334: A Context-Aware ALK5 Research Guide
2026-09-10
SB525334 is a selective TGF-beta1 receptor inhibitor for dissecting ALK5-dependent signaling in fibrosis and renal disease models. This guide connects compound-level assay design with new evidence showing that TGF-β1 signaling can either drive pathology or support diabetic wound repair.
-
Estradiol, ER Stress, and T-Cell Recovery After Shock
2026-09-09
The reference study identifies endoplasmic reticulum stress as a mechanistic link between hemorrhagic shock and impaired splenic CD4+ T-lymphocyte function. Pharmacological experiments indicate that estradiol acts mainly through ERα and GPR30, rather than ERβ, to reduce this stress response and restore immune-cell activity.
-
MK-8745: Aurora A Inhibitor Workflows
2026-09-09
MK-8745 provides a potent, selective way to connect Aurora A activity with mitotic arrest, apoptosis, and tumor-response phenotypes. This practical guide translates retinoblastoma findings into cell-based assay design while covering formulation, controls, readouts, and troubleshooting.
-
PF-562271 HCl for Reliable FAK/Pyk2 Assays
2026-09-08
Learn how PF-562271 HCl, SKU A8345, can support reproducible viability, proliferation, and cytotoxicity workflows through defined FAK/Pyk2 potency, documented solvent behavior, and practical assay controls. This scenario-based guide separates target-engagement evidence from nonspecific cell loss and provides recommendations for handling, interpretation, and vendor selection.
-
CCG-1423: RhoA Inhibitor Mechanism & Use
2026-09-08
CCG-1423 is a small-molecule RhoA inhibitor that blocks MRTF-A nuclear import by disrupting its interaction with importin α/β1. Its research applications include cancer research, proliferation studies, invasion models, and apoptosis assays, while its relevance to virus-associated barrier remodeling remains a hypothesis rather than a demonstrated treatment effect.